AQST officer reports tax-withheld 76,147 shares

Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender reported a routine tax-related share disposition.

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender reported a routine tax-related share disposition. On May 5, 2026, 76,147 shares of common stock were withheld at $4.18 per share to cover her tax withholding obligation tied to vesting Performance Stock Units.

These shares were retained by the company rather than sold in the open market. After this withholding, Braender directly owned 366,732 shares of Aquestive Therapeutics common stock, indicating she continues to hold a substantial equity position.

Insider Trade Summary

Exercise Price or Tax Liability: 76,147 shares

Exercise Price or Tax Liability 1 txn

Insider BRAENDER LORI J

Role Corporate Secretary

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	76,147	$4.18	$318K

Holdings After Transaction: Common Stock — 366,732 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Key Figures

Shares withheld for taxes: 76,147 shares Withholding price per share: $4.18 per share Shares owned after transaction: 366,732 shares

3 metrics

Shares withheld for taxes 76,147 shares Withheld on May 5, 2026 to satisfy tax obligation

Withholding price per share $4.18 per share Price used for tax-withholding disposition

Shares owned after transaction 366,732 shares Direct common stock holdings after tax withholding

Key Terms

Performance Stock Units, tax withholding obligation, Form 4

3 terms

Performance Stock Units financial

"in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

tax withholding obligation financial

"shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

Form 4 regulatory

"INSIDER FILING DATA (Form 4): {"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AQST’s Corporate Secretary report on this Form 4?

AQST’s Corporate Secretary, Lori J. Braender, reported a tax-related disposition where 76,147 common shares were withheld at $4.18 per share to satisfy tax obligations from vesting Performance Stock Units, rather than being sold on the open market.

Did the AQST insider sell shares in the open market in this Form 4?

No open market sale occurred. The 76,147 AQST shares were withheld by the company to satisfy Corporate Secretary Lori J. Braender’s tax withholding obligation from vesting Performance Stock Units, a routine administrative transaction, not a discretionary market trade.

How many AQST shares were withheld for taxes and at what price?

A total of 76,147 Aquestive Therapeutics common shares were withheld at a price of $4.18 per share. This withholding covered Corporate Secretary Lori J. Braender’s tax obligation arising from the vesting of previously granted Performance Stock Units.

How many AQST shares does the insider hold after this tax withholding?

Following the tax withholding transaction, Corporate Secretary Lori J. Braender directly holds 366,732 shares of Aquestive Therapeutics common stock. This figure reflects her remaining direct ownership after 76,147 shares were withheld to cover her tax obligation.

What triggered the AQST tax-withholding disposition reported on this Form 4?

The disposition was triggered by the vesting of certain Performance Stock Units previously granted to Lori J. Braender. To meet her tax withholding obligation from that vesting, 76,147 AQST common shares were withheld by the issuer instead of delivering all vested shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 05:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRAENDER LORI J

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Corporate Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		F		76,147(1)	D	$4.18	366,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Remarks:

Former Chief Legal Officer and Chief Compliance Officer

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)